allogeneic hematopoietic stem cell transplantation + FLUDARABINE PHOSPHATE + Cyclophosphamide + Mycophenolate Mofetil + Busulfan + Tacrolimus for graft vs host disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Sep 2014: Trial registered, NCT02248597
  2. 25 Feb 2015: Trial started, NCT02248597

The trials

NCT02248597: Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases

State
Completed
Phase
Phase 2
People
27 taking part
Started
25 Feb 2015
Primary completion
18 Jan 2022
Arms
Treatment (stem cell transplant with GVHD prophylaxis)
Results
Posted on the registry
  1. 25 Sep 2014: Trial registered
  2. 25 Feb 2015: Trial started
  3. 18 Jan 2023: Trial completed
  4. 11 Oct 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.